Hence, from a clinical perspective, the importance of understanding further the AVP involvement in stroke-elicited damage progression as copeptin, as it is secreted in equimolar concentrations as AVP and has been considered a surrogate marker of AVP, is an effective biomarker in terms of risk stratification after ischemic stroke and in predicting vascular events after a transient ischemic attack (TIA) [21,26]. This evidence concerns the gene AVP and transient ischemic attack.